Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma.

Julio C Chavez,Francine M Foss,Basem M William,Jonathan E Brammer,Sonali M Smith,Anca Prica,Jasmine M Zain,Joseph M Tuscano,Harsh Shah,Neha Mehta-Shah,Praveen Ramakrishnan Ramakrishnan Geethakumari,Ben X Wang, Stephanie Zantinge, Lisa Wang,Ling Zhang,Anmarie Boutrin,Weiguang Zhao,Lily Cheng,Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao,Shringi Sharma,Gianluca Carlesso,Jeffrey A Moscow,Lillian L Siu

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 5|浏览44

暂无评分

摘要

MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.

查看译文

关键词

t-cell,t-follicular,t-cell,t-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要